Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LMAT Stock Forecast 2026-2027
$107.94
Current Price
$2.47B
Market Cap
Buy 6
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to LMAT Price Targets
+25.1%
To High Target of $135.00
+8.4%
To Median Target of $117.00
-12.9%
To Low Target of $94.00
LMAT Price Momentum
-3.2%
1 Week Change
-5.8%
1 Month Change
+34.5%
1 Year Change
+33.1%
Year-to-Date Change
-8.5%
From 52W High of $118.01
+37.8%
From 52W Low of $78.35
📊 TOP ANALYST CALLS
Did LMAT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LeMaitre is one of their latest high-conviction picks.
Latest LMAT Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, LMAT has a bullish consensus with a median price target of $117.00 (ranging from $94.00 to $135.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $107.94, the median forecast implies a 8.4% upside. This outlook is supported by 6 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Nathan Treybeck at Wells Fargo, suggesting a 12.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LMAT Analyst Ratings
6
Buy
4
Hold
0
Sell
LMAT Price Target Range
Low
$94.00
Average
$117.00
High
$135.00
Current: $107.94
Latest LMAT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LMAT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2026 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $104.00 |
| May 6, 2026 | Citizens | Daniel Stauder | Market Outperform | Maintains | $127.00 |
| May 6, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $120.00 |
| Feb 26, 2026 | Citizens | Daniel Stauder | Market Outperform | Maintains | $118.00 |
| Feb 26, 2026 | Roth Capital | Kyle Bauser | Buy | Reiterates | $117.00 |
| Feb 26, 2026 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $94.00 |
| Feb 26, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $105.00 |
| Feb 20, 2026 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Nov 7, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $93.00 |
| Nov 5, 2025 | Roth Capital | Kyle Bauser | Buy | Reinstates | $108.00 |
| Oct 15, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Sep 23, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $95.00 |
| Aug 6, 2025 | Barrington Research | Michael Petusky | Outperform | Upgrade | $95.00 |
| Aug 6, 2025 | Cantor Fitzgerald | Ross Osborn | Neutral | Maintains | $95.00 |
| Jul 22, 2025 | Barrington Research | Michael Petusky | Market Perform | Reiterates | $N/A |
| Feb 28, 2025 | Lake Street | Brooks O'Neil | Buy | Maintains | $110.00 |
| Feb 28, 2025 | Citizens Capital Markets | Daniel Stauder | Buy | Maintains | $110.00 |
| Feb 28, 2025 | Barrington Research | Michael Petusky | Market Perform | Downgrade | $N/A |
| Feb 13, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Initiates | $95.00 |
| Nov 1, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $93.00 |
Lemaitre Vascular Inc. (LMAT) Competitors
The following stocks are similar to LeMaitre based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LMAT
LeMaitre Vascular
mkt cap
2.47B
Lemaitre Vascular Inc. (LMAT) Financial Data
Lemaitre Vascular Inc. has a market capitalization of $2.47B with a P/E ratio of 39.9x. The company generates $256.28M in trailing twelve-month revenue with a 24.3% profit margin.
Revenue growth is +11.2% quarter-over-quarter, while maintaining an operating margin of +26.7% and return on equity of +16.5%.
Valuation Metrics
Market Cap
$2.47B
Enterprise Value
$2.28B
P/E Ratio
39.9x
PEG Ratio
1.0x
Price/Sales
9.7x
Growth & Margins
Revenue Growth (YoY)
+11.2%
Gross Margin
+72.7%
Operating Margin
+26.7%
Net Margin
+24.3%
EPS Growth
+42.4%
Financial Health
Cash/Price Ratio
+14.9%
Current Ratio
14.3x
Debt/Equity
46.7x
ROE
+16.5%
ROA
+7.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lemaitre Vascular Inc. (LMAT) Business Model
About Lemaitre Vascular Inc.
What They Do
Develops medical devices for vascular surgery.
Business Model
The company generates revenue by developing, manufacturing, and marketing specialized medical devices and implants for vascular surgery. Its comprehensive product portfolio includes allografts, embolectomy and thrombectomy catheters, and various grafts and patches, which it sells directly to hospitals and through distributors worldwide.
Additional Information
Founded in 1986 and headquartered in Burlington, Massachusetts, the company serves a global market with a strong focus on the U.S. revenue stream. LeMaitre also offers human tissue cryopreservation services, enhancing its product offerings in the vascular surgery field.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
646
CEO
Mr. George W. LeMaitre
Country
United States
IPO Year
2006
Website
www.lemaitre.comLemaitre Vascular Inc. (LMAT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre (LMAT) delivered earnings and revenue surprises of +2.52% and -0.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 05, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
LeMaitre Vascular, Inc. (LMAT) held its Q1 2026 earnings call, detailing financial performance and strategic updates for investors. Further specifics can be found in the full transcript.
Why It Matters
LeMaitre Vascular's Q1 2026 earnings reveal financial performance, growth trends, and strategic direction, impacting stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
LeMaitre Q1 2026 Financial Results
5 days ago
Quick Summary
LeMaitre Vascular, Inc. (Nasdaq: LMAT) reported Q1 2026 results and announced a quarterly dividend of $0.25 per share. Guidance for the upcoming period was also provided.
Why It Matters
LeMaitre Vascular's Q1 results and dividend announcement indicate financial health and shareholder returns, while guidance signals future performance expectations, influencing stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
LeMaitre Vascular (LMAT) reported quarterly earnings of $0.68 per share, surpassing the Zacks Consensus Estimate of $0.66 and up from $0.48 per share year-over-year.
Why It Matters
LeMaitre Vascular's earnings beat expectations and show significant year-over-year growth, indicating strong financial performance and potential for future stock price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LeMaitre Vascular, Inc. (Nasdaq: LMAT) will present at the Bank of America Healthcare Conference on May 13, 2026, at 5:15 PM PT.
Why It Matters
LeMaitre Vascular's presentation at a key healthcare conference may influence investor sentiment, potentially impacting stock performance and market perception of the company's growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
LeMaitre (LMAT) Upgraded to Buy: Here's Why
3 days ago
Quick Summary
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could positively impact the stock price.
Why It Matters
LeMaitre's upgrade to a Zacks Rank #2 signals positive earnings outlook, potentially boosting investor confidence and leading to stock price increases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LeMaitre (LMAT) is positioned to outperform the market, showing above-average growth in its financials.
Why It Matters
LeMaitre's above-average growth signals strong financial health, potentially leading to higher returns and making it an attractive investment option.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About LMAT Stock
What is Lemaitre Vascular Inc.'s (LMAT) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Lemaitre Vascular Inc. (LMAT) has a median price target of $117.00. The highest price target is $135.00 and the lowest is $94.00.
Is LMAT stock a good investment in 2026?
According to current analyst ratings, LMAT has 6 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $107.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LMAT stock?
Wall Street analysts predict LMAT stock could reach $117.00 in the next 12 months. This represents a 8.4% increase from the current price of $107.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lemaitre Vascular Inc.'s business model?
The company generates revenue by developing, manufacturing, and marketing specialized medical devices and implants for vascular surgery. Its comprehensive product portfolio includes allografts, embolectomy and thrombectomy catheters, and various grafts and patches, which it sells directly to hospitals and through distributors worldwide.
What is the highest forecasted price for LMAT Lemaitre Vascular Inc.?
The highest price target for LMAT is $135.00 from at , which represents a 25.1% increase from the current price of $107.94.
What is the lowest forecasted price for LMAT Lemaitre Vascular Inc.?
The lowest price target for LMAT is $94.00 from Nathan Treybeck at Wells Fargo, which represents a -12.9% decrease from the current price of $107.94.
What is the overall LMAT consensus from analysts for Lemaitre Vascular Inc.?
The overall analyst consensus for LMAT is bullish. Out of 15 Wall Street analysts, 6 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $117.00.
How accurate are LMAT stock price projections?
Stock price projections, including those for Lemaitre Vascular Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:12 AM UTC